香港股市 將在 5 小時 56 分鐘 開市
  • 恒指

    18,597.23
    +392.55 (+2.16%)
     
  • 國指

    6,374.44
    +137.72 (+2.21%)
     
  • 上證綜指

    3,151.34
    +1.59 (+0.05%)
     
  • 道指

    34,200.14
    +347.61 (+1.03%)
     
  • 標普 500

    4,032.20
    +74.57 (+1.88%)
     
  • 納指

    11,323.21
    +339.43 (+3.09%)
     
  • Vix指數

    20.47
    -1.42 (-6.49%)
     
  • 富時100

    7,573.05
    +61.05 (+0.81%)
     
  • 紐約期油

    80.47
    +2.27 (+2.90%)
     
  • 金價

    1,776.20
    +12.50 (+0.71%)
     
  • 美元

    7.8051
    -0.0049 (-0.06%)
     
  • 人民幣

    0.9078
    -0.0083 (-0.91%)
     
  • 日圓

    0.0562
    +0.0001 (+0.21%)
     
  • 歐元

    8.1079
    +0.0459 (+0.57%)
     
  • Bitcoin

    17,081.14
    +644.26 (+3.92%)
     
  • CMC Crypto 200

    405.84
    +5.15 (+1.28%)
     

Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders

  • The European Commission approved Roche Holding AG's (OTC: RHHBY) Vabysmo (faricimab) for neovascular or 'wet' age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME).

  • These retinal conditions affect more than 40 million people globally.

  • Vabysmo is the only injectable eye medicine approved in Europe, with phase 3 studies supporting treatment at intervals of up to four months for people living with nAMD and DME.

  • Also ReadWHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete

  • The approval is based on four phase 3 studies involving 3,220 patients. The studies showed that people treated with Vabysmo, up to every four months, achieved similar outcomes compared to those receiving treatment every two months with aflibercept.

  • The totality of data across all four studies at two years showed that more than 60% of people treated with Vabysmo could extend treatment to every four months while improving and maintaining vision.

  • Additionally, for up to two years, people with nAMD and DME treated with Vabysmo received 33% (10 vs. 15) and 21% (11 vs. 14) fewer median number of injections than aflibercept, respectively.

  • Vabysmo is now approved in the European Union and nine other countries. Globally, more than 100,000 Vabysmo doses have been distributed.

  • Price Action: RHHBY shares traded lower by 1.70% at $41.63 on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.